LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Colorectal Cancer
			Esophageal Cancer
			Gastric Cancer
			Pancreatic Cancer
2		Additional conditions recognized in this trial
			Adenocarcinoma
			Colorectal Neoplasms
			Esophageal Diseases
			Esophageal Neoplasms
			Pancreatic Neoplasms
			Rectal Neoplasms
			Stomach Neoplasms
3		More general conditions related to this trial
			Carcinoma
			Colonic Diseases
			Digestive System Diseases
			Digestive System Neoplasms
			Endocrine Gland Neoplasms
			Endocrine System Diseases
			Gastrointestinal Diseases
			Gastrointestinal Neoplasms
			Head and Neck Neoplasms
			Intestinal Diseases
			Intestinal Neoplasms
			Neoplasms
			Neoplasms by Histologic Type
			Neoplasms by Site
			Neoplasms, Glandular and Epithelial
			Pancreatic Diseases
			Rectal Diseases
			Stomach Diseases
4		Interventions listed in this trial
			LMB-9 immunotoxin
5		Additional drug interventions recognized in this trial
			Immunotoxins
6		More general drug interventions related to this trial
			Immunologic Factors
			Pharmacologic Actions
			Physiological Effects of Drugs
7		Sponsors listed in this trial
			University Hospital Freiburg
			National Cancer Institute (NCI)